Current and novel therapeutic targets in the treatment of rheumatoid arthritis

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a complex autoimmune disease causing joint damage and functional impairment.
• Current RA treatments have limitations, including side effects and lack of efficacy in 20-40% of patients.
• There is a significant unmet need for innovative RA therapeutic strategies.

Purpose of the Study:

• To review critical molecular pathways in RA pathogenesis.
• To discuss the potential of novel therapeutic targets for RA treatment.
• To highlight emerging targets beyond established pathways.

Main Methods:

• Literature review of key molecular pathways implicated in RA.
• Analysis of the physiological and pharmacological relevance of potential therapeutic targets.
• Discussion of established and emerging targets in RA.

Main Results:

• Identified Janus kinase/signal transducer and activator of transcription (JAK/STAT), Th17, and hypoxia-inducible factor (HIF) pathways as critical targets.
• Discussed the role of these pathways in RA synovitis, cartilage destruction, and bone erosion.
• Explored less developed targets such as NLRP3 inflammasome and HDAC1.

Conclusions:

• Targeting JAK/STAT, Th17, and HIF pathways offers promising avenues for novel RA therapies.
• Emerging targets like NLRP3 inflammasome and HDAC1 warrant further investigation for RA treatment.
• Developing new RA treatments is crucial to address patient populations unresponsive to current therapies.